Kenvue Inc. (NYSE:KVUE) Shares Acquired by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 143.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,938 shares of the company’s stock after acquiring an additional 28,216 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Kenvue were worth $1,023,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Grove Bank & Trust increased its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. grew its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the third quarter valued at approximately $35,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on KVUE shares. Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $23.75.

Kenvue Trading Up 2.0 %

Shares of Kenvue stock opened at $23.90 on Tuesday. The company has a fifty day simple moving average of $21.69 and a 200-day simple moving average of $22.35. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $45.67 billion, a price-to-earnings ratio of 45.09, a PEG ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.43%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.